FDA approves MannKind's Afrezza?
Current prediction market odds for FDA approves MannKind's Afrezza. Track market probability, sentiment, key developments and forecast changes. Current probability: 97%.
Current Odds
Current prediction market probability
Why the Odds Changed
U.S. regulators are expected to approve MannKind's inhaled insulin Afrezza for children and adolescents with diabetes by late May 2026.
Recent Developments
The U.S. Food and Drug Administration is expected to approve MannKind's Afrezza for use in children and adolescents with type 1 or type 2 diabetes, potentially expanding access to the inhaled insulin treatment beyond its current adult patient base. A decision is anticipated around May 29, 2026, with any final action expected shortly thereafter.
Approval would mark a significant label expansion for Afrezza, which is designed to provide rapid-acting insulin through inhalation rather than injection. The decision could offer pediatric endocrinologists and families an additional mealtime insulin option, particularly for patients seeking alternatives to injected rapid-acting insulin.
MannKind would likely be subject to standard post-approval requirements if regulators grant clearance, including safety monitoring and any pediatric-specific labeling conditions. The company and clinicians are expected to focus closely on dosing guidance, pulmonary safety, and appropriate patient selection as the therapy moves toward broader pediatric use.
Market Sentiment
A 97% probability means traders currently view this outcome as highly likely. AlphaNews monitors this forecast as the market reacts to new information.
Key Risks
Prediction market probabilities can change quickly when new evidence, liquidity, deadlines or market rules shift. Treat this page as a live forecast, not a guarantee.
